Fukatsu T, Nakashima N, Takeuchi J
Department of Laboratory Medicine, Nagoya University School of Medicine.
Rinsho Byori. 1992 Feb;40(2):133-8.
Values of CA125, CA19-9, TPA, CA72-4, BFP and LDH in sera were detected in 148 malignant ovarian tumors, 41 borderline malignant ovarian tumors, 71 benign ovarian tumors and 64 benign uterine diseases. A new cut-off value was determined by ROC graph for distinguishing malignant and borderline ovarian tumors from benign ovarian tumors. CA125 (cut off: 30 U/ml) was a highly sensitive marker for malignant and borderline malignant ovarian tumors, the value being 88.1% (52/59) and 81.8% (9/11), respectively. On the other hand, in 37 benign ovarian tumors, the positive rate was 21.6% and in 21 benign uterine diseases it was 52.4%. CA19-9 (cut off: 150 U/ml) was inferior to CA125, but it was an effective marker for mucinous ovarian tumors. TPA (cut off: 40 U/ml) was also a sensitive (84.7%, 50/59) marker of malignant ovarian tumors. CA72-4 (cut off: 4 U/ml) was a highly specific (87.0%, 60/69) marker of malignant ovarian tumors. Combination assays of CA125/CA19-9, CA125/TPA and CA125/CA72-4 were not effective. Usefulness of BFP for early malignant ovarian tumors was suggested. Seven cases of dysgerminoma showed extremely elevated LDH levels (1,248 +/- 886 IU/1/37 degrees C). Malignancy and histological type of ovarian tumors could be decided by combination assay of these tumor markers, before surgical operation.
对148例恶性卵巢肿瘤、41例交界性恶性卵巢肿瘤、71例良性卵巢肿瘤和64例良性子宫疾病患者检测了血清中CA125、CA19-9、组织多肽抗原（TPA）、CA72-4、碱性胎儿蛋白（BFP）和乳酸脱氢酶（LDH）的值。通过ROC曲线确定了一个新的临界值，用于区分恶性和交界性卵巢肿瘤与良性卵巢肿瘤。CA125（临界值：30 U/ml）是恶性和交界性恶性卵巢肿瘤的高敏标志物，其阳性率分别为88.1%（52/59）和81.8%（9/11）。另一方面，在37例良性卵巢肿瘤中阳性率为21.6%，在21例良性子宫疾病中为52.4%。CA19-9（临界值：150 U/ml）不如CA125，但它是黏液性卵巢肿瘤的有效标志物。TPA（临界值：40 U/ml）也是恶性卵巢肿瘤的敏感标志物（84.7%，50/59）。CA72-4（临界值：4 U/ml）是恶性卵巢肿瘤的高特异性标志物（87.0%，60/69）。CA125/CA19-9、CA125/TPA和CA125/CA72-4联合检测无效。提示BFP对早期恶性卵巢肿瘤有诊断价值。7例无性细胞瘤患者的LDH水平极度升高（1248±886 IU/1/37℃）。在手术前，通过这些肿瘤标志物的联合检测可以确定卵巢肿瘤的恶性程度和组织学类型。
